Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom

Background Treatment paradigms in autoimmune hepatitis (AIH) have remained largely unchanged for decades. Studies report ≤20% of patients have sub‐optimal treatment response with most requiring long‐term therapy.